Biology Reference
In-Depth Information
Oskam R, Rijksen G, Staal GEJ, Vora S (1985) Isozymic composition and regulatory properties of
phosphofructokinase from well-differentiated and anaplastic medullary thyroid carcinomas of
the rat. Cancer Res 45:135-42
Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH (2002) Mitochondrial bound type II
hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for
therapeutic intervention. Biochem Biophys Acta 1555:14-20
Pelicano H, Martin DS, Xu RH, Hung P (2006) Glycolysis inhibition for anticancer treatment.
Oncogene 25:4633-46
Ralph SJ, Rodr´guez-Enr´quez S, Neuzil J, Moreno-S´nchez R (2010a) Bioenergetic pathways in
tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced
apoptotic trigger. Mol Aspects Med 31:29-59
Ralph SJ, Rodr
´
guez-Enr
´
quez S, Neuzil J, Saavedra E, Moreno-S
´
nchez R (2010b) The causes of
cancer revisited: “mitochondrial malignancy” and ROS-induced oncogenic transformation:
why mitochondria are targets for cancer therapy. Mol Aspects Med 31:145-70
Rodr
´
guez-Enr
´
quez S, Torres-M
´
rquez ME, Moreno-S
´
nchez R (2000) Substrate oxidation and
ATP supply in AS-30D hepatoma cells. Arch Biochem Biophys 375:21-30
Rodr
´
guez-Enr
´
quez S, Mar
´
n-Hern
´
ndez A, Gallardo-P
´
rez JC, Moreno-S
´
nchez R (2009) Kinet-
ics of transport and phosphorylation of glucose in cancer cells. J Cell Physiol 221:552-9
Saavedra E, Mar´n-Hern´ndez A, Encalada R, Olivos A, Mendoza-Hern´ndez G, Moreno-S´nchez
R (2007) Kinetic modeling can describe
in vivo
glycolysis in
Entamoeba histolytica
. FEBS J
274:4922-40
Segel IH (1975) Enzyme kinetics. Wiley, New York
Sheng H, Niu B, Sun H (2009) Metabolic targeting of cancers: from molecular mechanisms to
therapeutic strategies. Curr Med Chem 16:1561-87
Siess EA, Nimmannit S, Wieland OH (1976) Kinetic and regulatory properties of pyruvate
dehydrogenase from Ehrlich ascites tumor cells. Cancer Res 36:55-9
Smith TAD (2000) Mammalian hexokinase and their abnormal expression in cancer. Br J Biomed
Sci 57:170-8
Sonveaux P, V´gran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ,
Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst
MW (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice.
J Clin Invest 118:3930-42
Soto AM, Sonnenschein C, Maini PK, Noble D (2011) Systems biology and cancer. Prog Biophys
Mol Biol 106:337-9
Staal GE, Kalff A, Heesbeen EC, van Veelen CW, Rijksen G (1987) Subunit composition,
regulatory properties, and phosphorylation of phosphofructokinase from human gliomas.
Cancer Res 47:5047-51
Stubbs M, Bashford CL, Griffiths JR (2003) Understanding the tumor metabolic phenotype in the
genomic era. Curr Mol Med 3:49-59
Teusink B, Walsh MC, van Dam K, Westerhoff HV (1998) The danger of metabolic pathways with
turbo design. Trends Biochem Sci 23:162-9
Teusink B, Passarge J, Reijenga CA et al (2000) Can yeast glycolysis be understood in terms of
in vitro kinetics of
the constituent enzymes? Testing biochemistry. Eur J Biochem
267:5313-29
van Gend C, Snoep JL (2008) Systems biology model databases and resources. Essays Biochem
45:223-6
Vannucci SJ, Seaman LB, Vannucci RC (1996) Effects of hypoxia-ischemia on GLUT1 and
GLUT3 glucose transporters in immature rat brain. J Cereb Blood Flow Metab 16:77-81
Vopel T, Makhatadze GI (2012) Enzyme activity in the crowded milieu. PLoS One 7:e39418
Vora S, Halper JP, Knowles DM (1985) Alterations in the activity and prolife of human phospho-
fructokinase during malignant transformation in vivo and in vitro: transformation and
progression-linked discriminants of malignancy. Cancer Res 45:2993-3001
Search WWH ::
Custom Search